Nilton Custodio, Marco Malaga, Rosa Montesinos, Diego Chambergo-Michilot, Fiorella Baca, Juan Carlos Carbajal, Jose Carlos Huilca, Eder Herrera-Perez, David Lira, Monica M Diaz, Serggio Lanata
INTRODUCTION: As disease modifying therapies become available, early detection of Alzheimer's disease (AD) becomes increasingly important. However, biomarkers in LMICs are rare and costly. Thus, we evaluated an AD-focused BCT, the Memory Alteration Test (M@T), to detect biomarker-proven AD and quantify its correlation with neurodegeneration and CSF AD biomarkers in a cohort of participants from Lima, Peru. METHODS: This is a secondary analysis of a cohort of 185 participants: 63 controls, 53 with amnestic MCI (aMCI), and 69 with dementia due to AD...
October 12, 2023: Dementia and Geriatric Cognitive Disorders